Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 seasonAchieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for